In our previous studies, we found that IL-17A could mediate anti-tumor immunity by recruiting immune cells to the tumor microenvironment, such as NK cells, CD8+ T cells and CD1a+ DCs [14, 15]. The gene discussed is CD1A; the disease is neoplasm.